| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
135,340,000 |
| Market
Cap: |
650.99(M) |
| Last
Volume: |
11,363,101 |
Avg
Vol: |
11,331,682 |
| 52
Week Range: |
$1.94 - $5.59 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
3,439,830 |
4,023,225 |
| Total Buy Value |
$0 |
$0 |
$10,277,564 |
$11,106,809 |
| Total People Bought |
0 |
0 |
12 |
12 |
| Total Buy Transactions |
0 |
0 |
14 |
42 |
| Total Shares Sold |
0 |
187,843 |
187,843 |
187,843 |
| Total Sell Value |
$0 |
$885,322 |
$885,322 |
$885,322 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pikover Yuri |
Director |
– • – |
2017-04-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
275,445 |
|
- |
|
| Neville Robert N |
Chief Executive OfficerOfficer |
• • – |
2017-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
378,135 |
|
- |
|
| Roberts Brandi |
Chief Financial Officer & SVP |
• – – |
2015-03-27 |
4 |
B |
$0.50 |
$8,950 |
D/D |
18,000 |
38,000 |
2.74 |
- |
|
| Roberts Brandi |
Chief Financial Officer & SVP |
• – – |
2015-03-26 |
4 |
B |
$0.50 |
$10,032 |
D/D |
20,000 |
20,000 |
2.74 |
- |
|
| Emanuele Robert Martin |
Senior VP, Development |
• – – |
2013-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
52,543 |
294,598 |
|
- |
|
| Emanuele Robert Martin |
Senior VP, Development |
• – – |
2012-12-13 |
4 |
D |
$0.00 |
$306 |
D/D |
(305,608) |
242,055 |
|
- |
|
| Ramsay David A |
Director |
– • – |
2012-05-14 |
4 |
B |
$0.54 |
$26,965 |
D/D |
50,000 |
100,000 |
2.39 |
- |
|
| Ramsay David A |
Director |
– • – |
2012-05-10 |
4 |
B |
$0.57 |
$22,612 |
D/D |
40,000 |
50,000 |
2.39 |
- |
|
| Ramsay David A |
Director |
– • – |
2012-05-09 |
4 |
B |
$0.55 |
$5,500 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Culley Brian M |
CEO and Director |
• • – |
2012-03-14 |
4 |
B |
$0.59 |
$12,103 |
D/D |
20,500 |
34,500 |
2.81 |
- |
|
| Emanuele Robert Martin |
Senior VP, Development |
• – – |
2011-12-16 |
4 |
AS |
$0.60 |
$24,432 |
D/D |
(41,000) |
547,663 |
|
- |
|
| Culley Brian M |
Chief Executive Officer |
• – – |
2011-06-02 |
4 |
AS |
$2.44 |
$12,200 |
D/D |
(5,000) |
0 |
|
- |
|
| Emanuele Robert Martin |
Senior VP, DevelopmentOfficer |
• – – |
2011-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
588,663 |
|
- |
|
| Culley Brian M |
Chief Executive Officer |
• – – |
2010-05-27 |
4 |
B |
$1.89 |
$9,450 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Robbins Joan M |
CSO, Sr. VP |
• – – |
2008-05-14 |
4 |
B |
$0.43 |
$2,150 |
D/D |
5,000 |
10,000 |
2.66 |
- |
|
| Robbins Joan M |
CSO, Sr. VP |
• – – |
2008-05-13 |
4 |
B |
$0.44 |
$2,200 |
D/D |
5,000 |
5,000 |
2.66 |
- |
|
| Levine Evan |
CEO & President |
• • – |
2008-02-08 |
4 |
B |
$0.50 |
$2,530 |
D/D |
5,000 |
4,395,000 |
2.73 |
- |
|
| Levine Evan |
CEO & President |
• • – |
2008-02-05 |
4 |
B |
$0.42 |
$2,130 |
D/D |
5,000 |
4,390,000 |
2.73 |
- |
|
| Levine Evan |
CEO & President |
• • – |
2008-02-04 |
4 |
B |
$0.42 |
$2,100 |
D/D |
5,000 |
4,385,000 |
2.73 |
- |
|
| Merritt James A |
President & Chf Med Officer |
• – – |
2007-12-14 |
4 |
B |
$0.44 |
$13,282 |
D/D |
30,000 |
35,000 |
2.74 |
- |
|
| Levine Evan |
CEO & Director |
• • – |
2007-12-14 |
4 |
B |
$0.44 |
$26,800 |
D/D |
60,000 |
60,000 |
2.81 |
- |
|
| Levine Evan |
CEO & President |
• • – |
2007-11-19 |
4 |
S |
$0.59 |
$1,770 |
D/D |
(3,000) |
4,380,000 |
|
- |
|
| Levine Evan |
CEO & President |
• • – |
2007-10-22 |
4 |
S |
$0.60 |
$601 |
D/D |
(1,000) |
4,383,000 |
|
- |
|
| Robbins Joan M |
CSO, Sr. VP |
• – – |
2007-09-07 |
4 |
AS |
$2.30 |
$18,400 |
I/I |
(8,000) |
146,500 |
|
- |
|
| Robbins Joan M |
CSO, Exec VP |
• – – |
2007-08-01 |
4 |
AS |
$2.35 |
$18,800 |
I/I |
(8,000) |
154,500 |
|
- |
|
239 Records found
|
|
Page 8 of 10 |
|
|
0.22 (4.79%) 
